IDEAYA Biosciences (IDYA) Projected to Post Earnings on Monday

Key Points

• IDEAYA will report Q1 2026 results before the market opens on Monday, May 11; analysts expect EPS of ($0.9888) and revenue of $5.038M, with a conference call set for Wednesday, May 13 at 12:30 PM ET.
• In the prior quarter (reported Feb. 17) IDEAYA beat estimates, posting EPS of ($0.94) versus a consensus of ($1.03) and revenue of $10.88M, up 55.7% year-over-year.
• Wall Street consensus is a “Moderate Buy” (15 Buys, 1 Hold, 1 Sell) with a target price of $50.44, and a director recently purchased 50,000 shares at $32.96 (insiders own 2.5%).

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) is expected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect IDEAYA Biosciences to post earnings of ($0.9888) per share and revenue of $5.0380 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.09. The firm had revenue of $10.88 million for the quarter, compared to analyst estimates of $5.95 million. During the same quarter in the previous year, the business posted ($1.49) earnings per share. IDEAYA Biosciences's revenue for the quarter was up 55.7% on a year-over-year basis. On average, analysts expect IDEAYA Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock opened at $28.19 on Monday. IDEAYA Biosciences has a 12-month low of $16.82 and a 12-month high of $39.28. The stock has a market cap of $2.48 billion, a P/E ratio of -21.52 and a beta of -0.04. The company has a 50-day moving average price of $32.20 and a 200 day moving average price of $32.96.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IDYA. UBS Group began coverage on shares of IDEAYA Biosciences in a research note on Wednesday, January 7th. They set a "buy" rating and a $50.00 target price for the company. Wall Street Zen raised shares of IDEAYA Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, April 18th. Wedbush increased their target price on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 14th. Guggenheim increased their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, April 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Fifteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.44.

Insider Activity at IDEAYA Biosciences

In other IDEAYA Biosciences news, Director Jeffrey Stein acquired 50,000 shares of the stock in a transaction dated Monday, March 2nd. The stock was acquired at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. boosted its stake in shares of IDEAYA Biosciences by 91.9% in the fourth quarter. Invesco Ltd. now owns 238,314 shares of the company's stock valued at $8,239,000 after purchasing an additional 114,118 shares during the period. XTX Topco Ltd acquired a new stake in IDEAYA Biosciences in the fourth quarter valued at approximately $2,288,000. Virtus Investment Advisers LLC raised its holdings in IDEAYA Biosciences by 53.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 7,819 shares of the company's stock valued at $270,000 after acquiring an additional 2,712 shares in the last quarter. Susquehanna Portfolio Strategies LLC raised its holdings in IDEAYA Biosciences by 24.0% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 202,434 shares of the company's stock valued at $6,998,000 after acquiring an additional 39,171 shares in the last quarter. Finally, Tang Capital Management LLC raised its holdings in IDEAYA Biosciences by 12.5% in the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company's stock valued at $15,556,000 after acquiring an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.